search

Active clinical trials for "Lentigo"

Results 1-10 of 45

Tolerance and Performance (Mode of Administration) of Cyto-selective Difluoroethane-based Cryotherapy...

Lentigo SolarSenile Lentigo

CS5_8 study aim to evaluate the tolerance and to adjust the mode of administration of 2 different conditions of cryotherapy treatments applied on the brown spots of the face with 1 prototype (816-v1). Each treatment corresponds to a specific frequency of cryogenic spray application. The study will evaluate the following prototype : • Prototypes from (816-v1 301) to (816-v1 355)

Recruiting22 enrollment criteria

TCA 15% Chemical Peel for Improvement in Hand Lentigines

PhotoagingLentigo

This study will evaluate the efficacy of the a 15% trichloroacetic acid + 3% glycolic acid peel combination for treatment of lentigines on the hands. This peel combination is sold over the counter. Patients will receive 3 treatments (spaced 4 weeks).

Recruiting9 enrollment criteria

Tolerance and Performance of Cyto-selective Difluoroethane-based Cryotherapy in the Treatment of...

Solar LentigoSenile Lentigo1 more

CS5_3 aims to evaluate the tolerance and to adjust the mode of administration of 4 different conditions of cryotherapy treatments applied on the brown spots of the face and hands with 3 prototypes. A brown spot is defined as solar or senile lentigo and post-inflammatory hyperpigmentation (PIH). Each treatment corresponds to a combination of a specific sequence of a cryogenic spray and of a frequency of application. The study will evaluate 3 prototypes : Prototype 1 : SN from (816-v1 001) to (816-v1 100) Prototype 2 : SN from (816-v1 101) to (816-v1 150) Prototype 3 : SN from (816-v1 151) to (816-v1 200) Prototypes will be applied on the face and hands according to specific frequencies of application.

Active22 enrollment criteria

Dinaciclib in Treating Patients With Stage IV Melanoma

Acral Lentiginous MelanomaCutaneous Nodular Melanoma5 more

This phase II trial is studying the side effects and how well dinaciclib works in treating patients with stage IV melanoma. Dinaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Active30 enrollment criteria

Radiotherapy or Imiquimod in Complex Lentigo Maligna

Lentigo Maligna

The purpose of this study is to investigate the effectiveness of using either radiotherapy (RT) or Imiquimod (ImiQ) to treat the Lentigo Maligna (LM), when surgery is not possible, is refused, or fails.

Active10 enrollment criteria

Tolerance and Performance of Cyto-selective Difluoroethane-based Cryotherapy in the Treatment of...

Solar LentigoSenile Lentigo1 more

CS5_7 study aim to evaluate the tolerance and to adjust the mode of administration of two conditions of cryotherapy treatment applied on the brown spots of the face and hands with 1 prototype (816-v1). A brown spot is defined as solar or senile lentigo and post-inflammatory hyperpigmentation (PIH). The study will evaluate the following prototype : • Prototypes from (816-v1 201) to (816-v1 290)

Not yet recruiting22 enrollment criteria

Performance and Tolerance of Cyto-selective Difluoroethane-based Cryotherapy in th Treatment of...

Solar LentigoSenile Lentigo

CS5_4 study aim to evaluate the performance and the tolerance of 3 prototypes of cyto-selective cryotherapy treatments applied on the brown spots on the face and hands of asian ethnicity skins (chinese). A brown spot is defined as solar or senile lentigo (SSL) and post-inflammatory hyperpigmentation (PIH). Each treatment corresponds to a combination of a specific sequence of cryogenic spray and of a frequency of application. Each spot will be treated by a defined prototype (always the same device on the same spot all along the study). The study will evaluate the following prototype : Prototypes 1 Prototypes 2 Prototypes 3

Not yet recruiting23 enrollment criteria

MRB 0.3% Serum Effectiveness on 2 Early Clinical Markers of Photoinduced Cutaneous Aging: Actinic...

Actinic KeratosisActinic Lentigo

The aim of this study is to evaluate effectiveness of a serum containing 0.3% of MRB, a cosmetic active ingredient, against actinic lentigo and actinic keratosis.

Not yet recruiting17 enrollment criteria

RASopathy Biorepository

RAS MutationNeurofibromatosis 112 more

The RASopathies are a group of developmental disorders caused by genetic changes in the genes that compose the Ras/mitogen activated protein kinase (MAPK) pathway. New RASopathies are being diagnosed frequently. This pathway is essential in the regulation of the cell cycle and the determination of cell function. Thus, appropriate function of this pathway is critical to normal development. Each syndrome in this group of disorders has unique phenotypic features, but there are many overlapping features including facial features, heart defects, cutaneous abnormalities, cognitive delays, and a predisposition to malignancies. This research study proposes to collect and store human bio-specimens from patients with suspected or diagnosed RASopathies. Once obtained, blood and/or tissue samples will be processed for: metabolic function studies, biomarkers, genetic studies, and/or the establishment of immortalized cell lines. In addition, data from the medical record (including neuropsychological evaluations) and surveys will be stored to create a longitudinal database for research conducted at CCHMC or at other research institutions.

Recruiting5 enrollment criteria

Complications and Recurrences After Mohs Micrographic Surgery and Slow Mohs

Skin CancerComplication8 more

Mohs micro-graphic surgery (Mohs) is a tissue-sparing, surgical treatment for different types of skin cancer (e.g. basal cell carcinoma, squamous cell carcinoma, lentigo maligna (melanoma). It is a procedure performed with frozen sections. Slow Mohs, a variant of micro-graphic surgery, is performed by formalin fixation and paraffin-embedded sections. Both in Mohs and Slow Mohs tumor margins are assessed to achieve complete removal. This study aims to investigate the clinical presentation and outcomes (i.e. complications and recurrence rates) in patients treated with Mohs or Slow Mohs in the dermatology department of the Maastricht University Medical Center+ in Maastricht, the Netherlands.

Recruiting3 enrollment criteria
12...5

Need Help? Contact our team!


We'll reach out to this number within 24 hrs